Latest Regulatory Approvals News

Excelsior Capital has settled its Federal Court dispute with London City Equities, paving the way for a capital return, fully franked dividend, and eventual delisting from the ASX.

Infomedia Ltd shareholders have overwhelmingly approved a scheme of arrangement for acquisition by TPG Capital, valuing the company at approximately AUD 651 million. The deal, supported by the board and an independent expert, is set to complete by early December 2025.

Nexus Minerals reports robust one-metre assay results from Clement and Godfrey prospects, confirming significant gold mineralisation at Wallbrook. The Crusader-Templar Mine Development and Closure Plan has secured regulatory approval, paving the way for operational progress.

SQX Resources has reported exceptional high-grade gold and silver assays from underground sampling at the Williams Project in Montana, validating historical data and advancing its acquisition of AM6 Pty Ltd.

Lunnon Metals has updated its Lady Herial gold resource to 36,300 ounces at 2.0 g/t, securing Gold Fields’ approval and nearing regulatory green light for mining.

Paradigm Biopharmaceuticals has drawn down US$5 million under its convertible note facility to fund the accelerated expansion of its global Phase 3 trial for knee osteoarthritis treatment.

Island Pharmaceuticals has secured FDA confirmation that its antiviral Galidesivir can proceed under the Animal Rule pathway for Marburg virus, qualifying for a lucrative Priority Review Voucher. This regulatory milestone accelerates the drug’s path to approval and potential government stockpile inclusion.

Algorae Pharmaceuticals has announced a non-renounceable Loyalty Options Offer to eligible shareholders, aiming to raise up to $337,678 before costs, with potential additional capital of $4.7 million if all options are exercised. The capital raise supports the company’s pharmaceutical and AI research and development ambitions.

Race Oncology has announced pivotal new clinical trials for its lead asset RC220, aiming to accelerate regulatory approval in Acute Myeloid Leukemia and tackle resistance in Non-Small Cell Lung Cancer.

TPG Telecom has launched a $688 million Reinvestment Plan offering new shares to eligible shareholders, aiming to offset the impact of a recent cash distribution and enhance market liquidity. The plan includes institutional and retail components priced at a discount, forming a key part of the company’s broader capital management strategy.

Tivan Limited has locked in a substantial $61.3 million equity investment from ETFS Capital, advancing the Speewah Fluorite Project in Western Australia and reinforcing its strategic partnerships with major Japanese stakeholders.

Radiopharm Theranostics has reached the halfway mark in enrolling patients for its Phase 2b trial of RAD101, a novel imaging agent targeting brain metastases. Early data suggest RAD101 may outperform MRI in distinguishing tumor recurrence from radiation damage.